Journal ArticleDOI
Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence
TLDR
In this paper, the authors provide information on the mechanisms of action of ICIs, review the efficacy results of clinical trials using ICIs for TNBC treatment, and assess the side effects of such drugs.About:
This article is published in International Immunopharmacology.The article was published on 2021-06-16. It has received 10 citations till now. The article focuses on the topics: Immune checkpoint & Triple-negative breast cancer.read more
Citations
More filters
Journal ArticleDOI
Black Phosphorus, an Emerging Versatile Nanoplatform for Cancer Immunotherapy.
TL;DR: In this paper, a photothermal agent based on black phosphorus nanosheets (BPNSs) and quantum dots (BPQDs) is proposed for photodynamic therapy (PDT).
Journal ArticleDOI
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
A. Rizzo,A. Cusmai,Silvana Acquafredda,Francesco Giovannelli,Luciana Rinaldi,A. Misino,G. Palmiotti +6 more
TL;DR: An overview of recent clinical studies of neoadjuvant immune checkpoint inhibitors in patients with triple-negative breast cancer, especially focusing on the recently presented and published KEYNOTE-522, IMpassion031 and GeparNUEVO trials is provided.
Journal ArticleDOI
Roles of HLA-G/KIR2DL4 in Breast Cancer Immune Microenvironment
Guoxu Zheng,Li Jia,Anderson Yang +2 more
TL;DR: The previous study had shown that HLA-G was a pivotal mediator of breast cancer resistance to trastuzumab, and blockade of the Hla-G/KIR2DL4 interaction can resensitize breast cancer to trastsimab treatment.
Journal ArticleDOI
Oncoinformatic screening of the gene clusters involved in the HER2-positive breast cancer formation along with the in silico pharmacodynamic profiling of selective long-chain omega-3 fatty acids as the metastatic antagonists.
Arwa Morshed,Salauddin Al Azad,Md. Abdur Rashid Mia,M. F. Uddin,T. Ema,Rukaiya Binte Yeasin,Sanjida Ahmed Srishti,Pallab K. Sarker,Rubaita Younus Aurthi,Farhan Jamil,Nure Sharaf Nower Samia,Partha Biswas,Iffat-Ara Sharmeen,Rasel Ahmed,Mahbuba Siddiquy,Nurunnahar +15 more
Journal ArticleDOI
Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes
TL;DR: Over-expressed WT-PD-L1 in human TNBC cells and in luminal-A breast cancer cells demonstrated that cell-autonomous PD-L 1 activities lead to increased tumor cell growth, invasion and release of pro-metastatic factors, which were promoted by PD-1 and were inhibited by mutating S283 in PD- L1.
References
More filters
Journal ArticleDOI
LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
David Miles,Joseph Gligorov,Fabrice Andre,David Cameron,Andreas Schneeweiss,Carlos Barrios,B H Xu,Andrew M Wardley,D. Kaen,L. Andrade,Vladimir Semiglazov,Mattea Reinisch,Monika Patre,Leilani Morales,Kenneth Russell,Margarita Donica,Joyce O'Shaughnessy +16 more
Journal ArticleDOI
NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
Ge Qin,Xin Wang,Shubiao Ye,Yizhuo Li,Miao Chen,Shusen Wang,Tao Qin,Changlin Zhang,Yixin Li,Qian Long,Huabin Hu,Dingbo Shi,Jiaping Li,Kai Zhang,Qinglian Zhai,Yanlai Tang,Tiebang Kang,Ping Lan,Fangyun Xie,Jianjun Lu,Wuguo Deng +20 more
TL;DR: NPM1 is revealed as a transcription regulator of PD-L1 in TNBC, which could lead to potential therapeutic strategies to enhance the efficacy of cancer immunotherapy.
Journal ArticleDOI
The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)
Nobumoto Tomioka,Manabu Azuma,Mayuko Ikarashi,Mitsugu Yamamoto,Masako Sato,Kenichi Watanabe,Katsushige Yamashiro,Masato Takahashi +7 more
TL;DR: The subset of TNBCs with Low-TILs and High-PD-L1 status could be the therapeutic target for immune checkpoint inhibitor.
Journal ArticleDOI
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.
Marcelo Sobral-Leite,Koen Van de Vijver,Magali Michaut,Rianne van der Linden,Gerrit K. J. Hooijer,Hugo M. Horlings,Tesa M. Severson,Anna Marie Mulligan,Anna Marie Mulligan,Nayana Weerasooriya,Joyce Sanders,Annuska M. Glas,Diederik Wehkamp,Lorenza Mittempergher,Kelly Kersten,Ashley Cimino-Mathews,Dennis Peters,Erik Hooijberg,Annegien Broeks,Marc J. van de Vijver,René Bernards,Irene L. Andrulis,Irene L. Andrulis,Marleen Kok,Karin E. de Visser,Marjanka K. Schmidt +25 more
TL;DR: PD-L1 is expressed on multiple immune cells (CD68+ macrophages, CD4+, FOXP3+, and CD8+ T cells) in the breast tumor microenvironment, independent of the PD- L1 status of the tumor cells, and there is no evidence that levels of PD-L 1+ TILs in TN breast cancer are driven by high mutation rate or BRCA1-like status.
Journal ArticleDOI
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer.
Cesar August Santa-Maria,Taigo Kato,Jae-Hyun Park,Kazuma Kiyotani,Alfred Rademaker,Ami N. Shah,Leeaht Gross,Luis Z. Blanco,Sarika Jain,Lisa Flaum,Claudia Tellez,Regina Stein,Regina Uthe,William J. Gradishar,Massimo Cristofanilli,Yusuke Nakamura,Francis J. Giles +16 more
TL;DR: Responses are low in unselected metastatic breast cancer, however, higher rates of clinical benefit were observed in TNBC and immunogenomic dynamics may help identify phenotypes most likely to respond to immunotherapy.
Related Papers (5)
Triple-Negative Breast Cancer: Immune Modulation as the New Treatment Paradigm
Mary L. Disis,Sasha E. Stanton +1 more
Checkpoint inhibitors in triple‐negative breast cancer (TNBC): Where to go from here
Maryann J. Kwa,Sylvia Adams +1 more